Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-01

Study Completion Date

2020-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. The aim of this approach is to improve pain management, and also to improve patient comfort. This study will assess patient discomfort symptoms before and after setting up intrathecal analgesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

NCT04459234

Cancer Chronic Pain Neuropathic Pain +1 more

COMPLETED

Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report

NCT04549818

Chronic Pain

UNKNOWN NA

Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units

NCT01094912

Pain

SUSPENDED NA

Early Treatment With Invasive Technique in Cancer Pain Management

NCT05594459

Cancer Pain Opioid Use

UNKNOWN NA

Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

NCT05674240

Cancer Pain Chronic Pain Cancer Associated Pain +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Descriptive multicenter study including patients with refractory cancer pain (unmanageable drug sides effects or intractable pain) who will receive intrathecal analgesia Patient discomfort symptoms will be evaluated before and after the beginning of intrathecal analgesia at 15, 30, 60 and 90 days.

Moreover, the impact on patient close relatives and on return home will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractory Cancer Pain Intrathecal Analgesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged 18 and older
* obligation of affiliation or beneficiary of a social security scheme
* patients with cancer and refractory localized cancer pain because of drug side effects or intractable pain
* localized pain in topography accessible to intrathecal analgesia (legs, abdomen and pelvis, pancoast-tobias symdrom)
* patient's informed consent for the study
* patient able to complete the evaluation questionnaires
* estimed vital prognosis more than three month
* patient with all conditions for intrathecal anagelsia

Exclusion Criteria

* patient with intracranial hypertension
* refusal of patient to be included in the study
* refusal of patient to receive intrathecal analgesia
* patient with many refractory pain localizations not accessible to intrathecal analgesia

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No